Pharma Mar Salute del bilancio
Salute finanziaria criteri di controllo 4/6
Pharma Mar ha un patrimonio netto totale di €182.2M e un debito totale di €50.8M, che porta il suo rapporto debito/patrimonio netto a 27.9%. Le sue attività totali e le sue passività totali sono rispettivamente €333.1M e €151.0M.
Informazioni chiave
27.9%
Rapporto debito/patrimonio netto
€50.84m
Debito
| Indice di copertura degli interessi | n/a |
| Contanti | €144.39m |
| Patrimonio netto | €182.17m |
| Totale passività | €150.96m |
| Totale attività | €333.13m |
Aggiornamenti recenti sulla salute finanziaria
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Recent updates
Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Oct 16Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Jul 28Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Jun 01Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
May 28Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( €238.0M ) di PHM superano le sue passività a breve termine ( €89.4M ).
Passività a lungo termine: Le attività a breve termine di PHM ( €238.0M ) superano le sue passività a lungo termine ( €61.5M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: PHM ha più liquidità del suo debito totale.
Riduzione del debito: Cinque anni fa, PHM aveva un patrimonio netto negativo, ma ora è positivo e quindi è migliorato.
Copertura del debito: Il debito di PHM non è ben coperto dal flusso di cassa operativo ( 3.2% ).
Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di PHM siano ben coperti dall'EBIT.